6505--Notice of Intent - Sole Source for Pluvicto 36C25225F0191
Summary
AI-generated · Aug 24, 2025Award of a sole-source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation for Pluvicto (Lutetium Lu-177 Vipivotide Tetraxetan), a highly specialized radiopharmaceutical indicated for adult PSMA-positive metastatic castration-resistant prostate cancer following AR pathway inhibition and taxane-based chemotherapy.
This is not a solicitation or competitive procurement. Interested parties may submit written evidence of capability by 5:00 p.m. ET on 08/26/2025, at no cost to the Government. Inquiries should be emailed to Parris.Weidenbach@va.gov (no phone requests). Any response must demonstrate that competition would be advantageous in future procurements.
The Department of Veterans Affairs, VHA Regional Procurement Office Central, Great Lakes Acquisition Center, Network Contracting Office 12, located at 115 S. 84th Street, Suite 101, Milwaukee, WI 53214-1476 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical. Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation. This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Parris.Weidenbach@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to Parris.Weidenbach@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.
From Special Notice posted on Aug 19, 2025Notice history
1-
Special Notice LATEST Posted Aug 19, 2025
Details
Award Information
Contacts
Contract Specialist
Phone